Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

While medications can help manage symptoms, many people with tardive dyskinesia are interested in natural therapies as an alternative or complementary approach. What the Research Says About Non ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Significantly increased risk for tardive dyskinesia seen with doses >75 mg/day at last prescription and as maximum dose.

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing ...

Wedbush analyst Laura Chico lowered the firm’s price target on Neurocrine (NBIX) to $147 from $157 and keeps an Outperform rating on the ...

Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...

Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study published in the Journal of Clinical Psychopharmacology. Maki Gouda ...